ImmunoGen, Inc.  

(Public, NASDAQ:IMGN)   Watch this stock  
Find more results for IMGN
7.60
-0.19 (-2.44%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.42 - 7.89
52 week 5.34 - 17.80
Open 7.83
Vol / Avg. 768,083.00/1.70M
Mkt cap 670.78M
P/E     -
Div/yield     -
EPS -0.85
Shares 86.11M
Beta 1.87
Inst. own 82%
Apr 23, 2015
Q3 2015 ImmunoGen Inc Earnings Release (Estimated) - 6:30AM EDT - Add to calendar
Mar 2, 2015
ImmunoGen Inc at Cowen Health Care Conference - 2:10PM EST - Add to calendar
Feb 24, 2015
ImmunoGen Inc at RBC Healthcare Conference
Feb 12, 2015
ImmunoGen Inc at Leerink Global Healthcare Conference
Jan 30, 2015
Q2 2015 ImmunoGen Inc Earnings Call - Webcast
Jan 30, 2015
Q2 2015 ImmunoGen Inc Earnings Release
Jan 13, 2015
ImmunoGen Inc at JPMorgan Healthcare Conference - Q&A Session - Webcast
Jan 13, 2015
ImmunoGen Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 28.23% -119.15%
Operating margin 28.53% -119.43%
EBITD margin - -111.75%
Return on average assets 40.27% -37.67%
Return on average equity 80.17% -72.25%
Employees 307 -
CDP Score - -

Address

830 WINTER ST
WALTHAM, MA 02451
United States - Map
+1-781-8950600 (Phone)
+1-781-8950611 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ImmunoGen, Inc. is a biotechnology company. The Company develops targeted anticancer therapeutics. The Company has three wholly-owned product candidates in clinical testing, with seven additional compounds in the clinic through its partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. The Company�s clinical-stage product candidates, include IMGN289, IMGN853 and IMGN529. IMGN289 compound is a treatment for many cases of head and neck cancers. IMGN853 compound is a potential treatment for epithelial ovarian cancer, endometrial cancer and other cancers. IMGN529 compound is used for the treatment of NHL (non-Hodgkin lymphoma). The Company�s IMGN529 ADC is a new treatment for cancers that express CD37, such as NHL and chronic lymphocytic leukemia.

Officers and directors

Stephen C. McCluski Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Daniel M. Junius President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Ellie Harrison Chief Human Resource Officer, Vice President
Age: 59
Bio & Compensation  - Reuters
Richard J Gregory Ph.D. Executive Vice President - Research, Chief Scientific Officer
Bio & Compensation  - Reuters
John M. Lambert Ph.D. Executive Vice President - Distinguished Research Fellow
Age: 63
Bio & Compensation  - Reuters
Sandra E. Poole Senior Vice President - Technical Operations.
Age: 51
Bio & Compensation  - Reuters
Craig Barrows Vice President, General Counsel, Secretary
Age: 59
Bio & Compensation  - Reuters
James J. O'Leary M.D. Vice President, Chief Medical Officer
Age: 50
Bio & Compensation  - Reuters
Peter J. Williams Vice President - Business Development
Age: 60
Bio & Compensation  - Reuters
Mark Goldberg Independent Director
Age: 60
Bio & Compensation  - Reuters